Impact of Lynch syndrome, BRAFV600E, and RAS mutations on outcomes in MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI): Analysis of combined international cohorts

with No hi ha comentaris
  • Colle, R., Lonardi, S., Cachanado, M., Overman, M. J., Elez, E., Fakih, M., . . . Andre, T. (2023). Impact of Lynch syndrome, BRAFV600E, and RAS mutations on outcomes in MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI): Analysis of combined international cohorts. Journal of Clinical Oncology, 41, 171-171. https://doi.org/10.1200/JCO.2023.41.4_suppl.171

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *